

NOVEL TETRAHYDROFUROBENZOFURANOXANTHONES FROM  
*PSOROSPERMUM FEBRIFUGUM*

Mohamed Abou-shoer, Khanit Suwanborirux, Ching-jer Chang, and John M. Cassady\*<sup>a</sup>.

Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907, U.S.A. <sup>a</sup>College of Pharmacy, The Ohio State University, Columbus, OH 43210, U.S.A.

**Abstract:** Two novel tetrahydrofurobenzofuranoxanthones, 1 and 2, were isolated from *Psorospermum febrifugum*. The structures and relative configurations were determined by MS, <sup>1</sup>H NMR, <sup>13</sup>C NMR spectroscopy and NOE experiments.

As a part of our investigation for antitumor agents from *Psorospermum febrifugum* Spach. (Guttiferae), the antitumor active psorospermin 5 and several active furanoxanthone analogs have been reported (1,2). In this paper, we report the isolation and structure elucidation of two novel xanthone analogs, 1 and 2, containing a new fused tetrahydrofurobenzofuran ring system. The compounds were isolated from the chloroform fraction of the ethanolic extract of the root bark of *Psorospermum febrifugum* by repeated chromatography on silica gel columns. The IR and UV spectra of 1 and 2 showed the similar presence of a xanthone carbonyl absorption at 1640 cm<sup>-1</sup> and of polyoxygenated xanthone nucleus absorptions at 247 and 312 nm, respectively.

Compound 1 was isolated as white crystals with mp. 266-268°C (decomp.) and [ $\alpha$ ]<sub>D</sub><sup>20</sup> = -83° (c = 0.15, MeOH). The molecular formula of the compound was determined as C<sub>19</sub>H<sub>16</sub>O<sub>7</sub> by high resolution EI mass spectrometry (M<sup>+</sup> obsd. 356.091, calcd. 356.090). The 470 MHz <sup>1</sup>H NMR spectrum (Table 1) showed the characteristic signals (1, 2) for the xanthone nucleus of the psorospermin group accounting for C<sub>14</sub>H<sub>8</sub>O<sub>4</sub>. The <sup>1</sup>H NMR signals of the remaining isoprenoid unit (C<sub>5</sub>H<sub>8</sub>O<sub>3</sub>) were assigned as a fused tetrahydrofurobenzofuran ring based on the following data. The doublet at 6.01 ppm (1'-H), typical for a benzylic methine proton directly bonded to an oxygenated carbon, was coupled to the doublet at 4.93 ppm (2'-H) with J = 5.6 Hz. These oxygenated methine carbons were also revealed by the 50 MHz <sup>13</sup>C NMR signals (Table 1) as two doublets at 79.3 ppm (C-1') and 90.2 ppm (C-2'), respectively (1). The proton signals at 3.67 and 3.17 ppm which appeared as two doublets (J = 9.6 Hz) were assigned to the methylene protons attached to the oxygenated carbon appearing as a triplet at 74.7 (C-4') in the <sup>13</sup>C NMR spectrum. The tertiary methyl group at 1.33 ppm and hydroxyl group at 5.38 ppm were bonded to the quaternary C-3' which appeared as a broad singlet at 77.9 ppm in the <sup>13</sup>C NMR spectrum.

The placement of this fused ring at the 3,4 position of the B-ring of the xanthone nucleus was confirmed by the intensity enhancement of the 2-H (39%) upon irradiation of 1-OCH<sub>3</sub> protons. Comparison of the 2'-H chemical shift at 4.93 of 1 with that of the

sterigmatocystin analog 6 at 6.75 ppm (3) suggested that 1 should differ in the oxygen arrangement from 6 in the side-chain ring. Finally, the fragment ion in eims at  $m/z$  282 due to two-bond cleavage of the side-chain ring (Fig.1) confirmed the proposed structure of 1.

The relative configurations at C-1', C-2', and C-3' were established by homonuclear NOE experiments from the acetate derivative 3 (4). Intensity enhancement of the 1'-H (13%) upon irradiation of the 2'-H suggested their *syn* relationship. Irradiation of the 3'-CH<sub>3</sub> enhancing 16% of the 2'-H, 6% of the 4'-H<sub>b</sub>, and 5% of the 4'-H<sub>a</sub> intensity, but no intensity enhancement for the 1'-H suggested that the 3'-CH<sub>3</sub> should be *anti* to the 1'-H and in a pseudoequatorial relationship to the 2'-H.




Figure 1 Fragmentation pattern of 1 and 2

Compound 2 was isolated as white fine crystals with mp. 216-217°C and  $[\alpha]_D^{25} = -75^\circ$  (c=0.06, MeOH). The molecular formula of 2 was established as  $C_{19}H_{16}O_8$  ( $M^+$  obs. 372.085, calcd. 372.085) by high resolution EIMS. The structure of 2 was closely related to 1 based on the UV, IR, MS, and NMR spectral data. The EIMS of 2 also yielded the fragment ion at m/z 282 indicating the typical xanthone moiety. However, the 470 MHz  $^1H$  NMR data (Table 1) of 2 showed the presence of a chelated phenolic proton at 13.22 which was assigned to the 1-OH (instead of 1-OCH<sub>3</sub> in 1) and was confirmed by a downfield shift of the C-2 proton upon acetylation (5). In addition, the  $^1H$  NMR and  $^{13}C$  NMR data of 2 also exhibited the typical signals for the fused bis-furan system. However, the presence of a proton triplet at 4.82 ppm (exchangeable with D<sub>2</sub>O) and an AB spin system of two double doublets at 3.68 and 3.55 ppm (collapsed to two doublets upon addition of D<sub>2</sub>O) indicated the presence of a CH<sub>2</sub>OH group which must reside at C-3'. This evidence was supported by a triplet at 62.0 ppm in the fully coupled  $^{13}C$  NMR spectrum. Therefore, the structure of this compound was proposed as 2. Compound 2 was determined to have the same relative configurations as 1 by NOE experiments of the acetate derivative 4. Irradiation of the 3'-CH<sub>2</sub> increased the intensities of the 2'-H (6%) and 4'-H<sub>b</sub> (9%) and irradiation of the 1'-H increased the intensity of the 2'-H (22%).

Table 1 470 MHz  $^1H$  and 50 MHz  $^{13}C$  NMR Data of 1 and 2<sup>a</sup>.

C#-H	1		2	
	$\delta C$	$\delta H(J)$	$\delta C$	$\delta H(J)$
C1	164.0,bs	-	148.1,bs	-
C2-H	94.2,bd	6.59,s	93.2,d	6.37,s
C3	165.8,bs	-	167.6,bs	-
C4	104.8,d	-	103.3,d	-
C4a	154.8,s	-	153.1,s	-
C5	146.0,d	-	164.9,d	-
C6-H	115.2,dd	7.21,dd (1.1,7.6)	115.8,dd	7.53,dd (1.3,8.0)
C7-H	123.9,d	7.17,t(7.6)	124.6,d	7.41,t(8.0)
C8-H	119.4,dd	7.47,dd (1.1,7.6)	117.3,dd	7.68,dd (1.3,8.0)
C8a	123.7,d	-	120.6,d	-
C9	173.4,d	-	180.0,d	-
C9a	106.4,d	-	103.9,d	-
G10a	143.4,dd	-	145.0,t	-
C1'-H	79.3,bd	6.01,d(5.6)	78.8,d	5.92,d(5.6)
C2'-H	90.2,d	4.93,d(5.6)	93.1,d	5.02,d(5.6)
C3'	77.9,bs	-	81.9,bs	-
C4'-Ha	74.7,bt	3.17,d(9.6)	72.5,t	3.27,d(9.8)
C4'-Hb	-	3.67,d(9.6)	-	3.71,d(9.8)
C5'-H	18.9,q	1.33,s	62.0,t	3.68,dd & 3.55,dd (4.0,11.5) <sup>b</sup>
1-OH	-	-	-	13.22,bs <sup>c</sup>
5-OH	-	10.30,b <sup>c</sup>	-	-
1-OCH <sub>3</sub>	56.5,q	3.86,s	-	-
5-OCH <sub>3</sub>	-	-	56.5,q	3.97,s
3'-OH	-	5.38,bs <sup>c</sup>	-	5.41,s <sup>c</sup>
5'-OH	-	-	-	4.82,bt(4.0) <sup>c</sup>

a) recorded in DMSO-d<sub>6</sub> ( $\delta$  in ppm, J in Hz). b) collapsed to doublets (J= 11.5 Hz) upon addition with D<sub>2</sub>O. c) exchangeable with D<sub>2</sub>O.

Biogenetically, the fused side-chain ring is probably derived from the quinone methide of the 1-hydroxybenzofuranxanthone via intramolecular nucleophilic attack by the 4'-OH of the hydroxyisopropyl side chain. Compound 1 showed borderline cytotoxicity in the colon carcinoma cell line (HT-29) at  $ED_{50} = 8 \mu\text{g/ml}$ , but 2 was inactive (6).

**Acknowledgements:** This investigation was supported by NIH Grant CA-33326. The 470 MHz  $^1\text{H}$  NMR spectra were performed at PUBMRL supported from NIH Grant RR01077 and NSF/BBS 8714248.

#### REFERENCES

1. Habib, A.M., Ho, D.K., Masuda, S., McCloud, T., Reddy, K.S., Abou-shoer, M., McKenzie, A., Byrn, S.R., Chang, C.-j., and Cassady, J.M., *J. Org. Chem.*, **52**, 412 (1987).
2. Abou-shoer, M., Boettner, F.E., Chang, C.-j., and Cassady, J.M., *Phytochemistry*, **27**, 2795 (1988).
3. Essery, J.M., O'Herron, F.A., McGregor, D.N., and Bradner, W.T., *J. Med. Chem.*, **19**, 1339 (1976).
4.  $^1\text{H}$  NMR (200 MHz,  $\text{DMSO-d}_6$ )  $\delta$  in ppm, 1.32 (3H, s, 5'- $\text{CH}_3$ ), 2.42 (3H, s, 5-OAc), 3.15 (1H, d,  $J = 9.6$ , 4'-Ha), 3.68 (1H, d,  $J = 9.6$ , 4'-Hb), 3.88 (3H, s, 1-O $\text{CH}_3$ ), 4.95 (1H, d,  $J = 5.9$ , 2'-H), 5.35 (1H, br s, 3'-OH), 5.92 (1H, d,  $J = 5.9$ , 1'-H), 7.41 (1H, t,  $J = 8.0$ , 7-H), 7.61 (1H, dd,  $J = 1.6, 8.0$ , 6-H), 7.94 (1H, dd,  $J = 1.6, 8.0$ , 8-H); CIMS  $m/z$ , 399 ( $\text{MH}^+$ ); IR (KBr) 3400, 1780, 1640, 1600  $\text{cm}^{-1}$ .
5.  $^1\text{H}$  NMR (200 MHz,  $\text{DMSO-d}_6$ )  $\delta$  in ppm, 2.07 (3H, s, 5'-OAc), 2.11 (3H, s, 3'-OAc), 2.37 (3H, s, 1-OAc), 3.59 (1H, d,  $J = 10.8$ , 4'-Ha), 3.95 (3H, s 5-O $\text{CH}_3$ ), 4.32 (1H, d,  $J = 10.8$ , 4'-Hb), 4.63 (1H, d,  $J = 11.5$ , 5'-Ha), 4.70 (1H, d,  $J = 11.5$ , 5'-Hb), 5.61 (1H, d,  $J = 6.0$ , 2'-H), 6.06 (1H, d,  $J = 6.0$ , 1'-H), 6.92 (1H, s, 2-H), 7.37 (1H, t,  $J = 7.8$ , 7-H), 7.49 (1H, dd,  $J = 1.5, 7.8$ , 6-H), 7.62 (1H, dd,  $J = 1.5, 7.8$ , 8-H); CIMS  $m/z$ , 499 ( $\text{MH}^+$ ); IR (KBr), 1770, 1750, 1660, 1630, 1590  $\text{cm}^{-1}$ .
6. Alley, M.C., Scudiero, D.C., Monks, A., Hursey, M.L., Czerwinski, M.J., Fine, D.L., Abbott B.J., Mayo, J.C., Shoemaker, R.H., and Boyd, M.R., *Cancer Res.*, **48**, 589 (1988).

(Received in USA 11 April 1989)